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ABSTRACT 
 
Introduction: 
The risk factors involved in treating transgender individuals with hormone 
therapy have been documented, but a full understanding of them remains 
elusive. Much of the research performed in transgender medicine is old or being 
completed overseas. It is thus the responsibility of current providers and 
investigators to expand our current knowledge, so this often marginalized 
population can receive the best quality care.  
Methods: 
 A group of 28 transgender men and women who received care from the 
Endocrinology Clinic at Boston Medical Center were randomly selected as part of 
a quality control project to evaluate the risk factors involved in hormone therapy. 
Analysis was two-fold. First, change in lab values associated with known risk 
factors over a two-year period were assessed in individual patients. Second, 
group analysis sought to correlate changing hormone levels with lab values 
associated with known risk factors. 
 
 v 
Results: 
 The result of the analysis was the majority of the patients who were 
observed did not suffer from any of the risk factors commonly associated with 
hormone therapy, and if anything benefited from the consistent clinical care. 
Several correlations were calculated between hormone levels and the lab values 
associated with the risk factors, however further analysis must be completed to 
confirm any connection. 
Discussion: 
 The goal of this project was to not only evaluate care at Boston Medical 
Center, but also to draw attention to transgender health. In doing so, we have 
given an example of safe and effective hormone therapy and shown additional 
avenues for future research.  
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INTRODUCTION  
Transsexual or transgender individuals have a condition characterized by 
an individual’s overwhelming desire to be of the opposite sex. Although this 
condition is not totally understood, investigators believe they have found a 
sexually dimorphic area of the brain. This area is called the bed nucleus of the 
stria terminalis (BST). The study of the BST has shown it is unaffected by sex 
hormone levels in adults and its volume is larger in men than in women. It was 
subsequently demonstrated that the BST volume of male to female (MtF) 
transgender individuals was comparable to that of genetic females. This 
discovery may provide a neurological basis for gender identity (Kruijver et al., 
2000; Zhou, Hofman, Gooren, & Swaab, 1995). That being said, more research 
must be done to fully understand the etiology of transgender individuals.  
Determining how prevalent transgender individuals are in the general 
population has proven to be a difficult task with variable results. This may be due 
to the rarity of the condition and changing political, cultural and social attitudes. 
Much of the data on prevalence and incidence are old, but there appears to be a 
trend towards increased incidence over time. A more recent study in the 
Netherlands found that in 1:11,900 males and 1:30,400 females identify as 
transgender (van Kesteren et al., 1996). A study of the Belgian population found 
a similar incidence (De Cuypere et al., 2007). While in Serbia the frequency is 
lower compared to Belgium and the Netherlands (Vujovic et al., 2009). With 
growing social acceptance, more prevalence studies will hopefully be performed, 
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which will give the medical community an opportunity to provide adequate care to 
these individuals.  
 Advancements in medicine and mental health have allowed for a more 
individualized treatment plan for transgender men and women seeking therapy. 
The choices for treatment include mental health counseling, hormone therapy 
and surgery. Transgender men and women have the option to pursue any 
combination of the three in order to accomplish their desired gender identity. 
Cross-sex hormones have a dual benefit for the gender-transitioning individual. 
First, they induce either feminization or virilization. Second, production of 
endogenous testosterone or estrogen is diminished through the suppression of 
the hypothalamic-pituitary-gonadal axis.  However, the administration of 
exogenous sex hormones is not without risks. Table 1 displays the variety of risk 
factors for which individuals may be subjected if they decide to take cross-sex 
hormones (Coleman et al., 2011). Many of these risk factors are not well 
understood, and thus would benefit from further clinical investigation.   
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Table 1: Risks Associated with Hormone Therapy (Coleman et al., 2011) 
 
 
Hyperprolactinemia or development of a prolactinoma results from over 
stimulation and hyperplasia of the lactotrophs in the anterior pituitary gland. This 
is a risk for MtF transgender individuals taking exogenous estrogen. With the 
correct dosage and preparation of estrogen the risk can usually be minimized, 
however if an individual has a pre-existing prolactinoma high-dose estrogen 
could exacerbate it (Coleman et al., 2011). The majority of data on 
hyperprolactinemia in MtF transgender individuals is twenty plus years old and 
consists mainly of case studies, so the understanding of this risk factor would 
benefit from a more population based perspective. The most recent large-scale 
study of transgender individuals measured prolactin levels. Their finding was that 
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hyperprolactinemia was very prevalent in the population. Of the 816 MtF 
transgender individuals studied, 14% had significantly increased prolactin levels 
(Van Kesteren et al. 1997). With its known risk, clinicians should diligently 
monitor prolactin levels.   
Much like the research done on hyperprolactinemia, the evidence for 
elevated liver enzymes and gallstones following hormone administration is old 
and in the form of case studies. Nevertheless the risk is present, and thus 
requires monitoring.  
The Van Kesteren et al. 1997 study once again provides us with an idea of the 
prevalence of these side effects. The investigators observed both temporary (<6 
months) and persistent (>6 months) increases in liver enzymes in both the MtF 
and FtM transgender individual study populations. Eleven percent of the 293 FtM 
participants and four percent of the 816 MtF participants had elevated liver 
enzymes. Three MtF participants developed gallstones during the study.  
The relationship between hormone therapy and Metabolic Syndrome is 
particularly interesting. Metabolic Syndrome is characterized by central obesity, 
dyslipidemia, hyperglycemia and hypertension (“What Is Metabolic Syndrome? - 
NHLBI, NIH,” n.d.). The markers of Metabolic Syndrome have been shown to 
increase the incidence of Type 2 Diabetes and cardiovascular disease. A full 
understanding of how hormone therapy in transgender individuals affects the 
symptoms of Metabolic Syndrome has proven to be elusive to clinicians and 
researchers. The reason for this is probably lack of research and data, however it 
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is also a difficult topic to study because of other confounding effects. For 
example feminizing and masculinizing hormones may have gender specific 
effects on cardiovascular disease. Evidence of this has been seen in men where 
low levels of serum testosterone are related to increased risk of cardiovascular 
disease (Rosano et al., 2007).  
From the clinical perspective however, when treating transgender 
individuals certain risk factors are generally accepted and supported by the 
available evidence. It has been shown that both MtF and FtM transgender 
individuals are susceptible to weight gain upon treatment with cross-sex 
hormones. Fat distribution can be considered gender specific, with men 
characteristically accumulating fat centrally or abdominally (android), while 
women are more likely to store fat subcutaneously in the hips and thighs 
(gynoid). A change in this typical presentation can be observed in transgender 
men and women undergoing hormone therapy. In a study observing size and 
lipolytic activity of abdominal and gluteal adipocytes in MtF and FtM transgender 
individuals a gender atypical fat distribution was observed. FtM subjects 
administered testosterone had a decrease in fat area in the hip region. While MtF 
subjects treated with estrogen and anti-androgen had an increase in 
subcutaneous fat in the hip region. Both MtF and FtM subjects saw an overall 
increase in body weight (Elbers et al., 1999).  
Gender transitioning individuals must also deal with the risk of a change in 
their lipid profile. Data from several studies have given clinicians an idea of what 
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to expect from cross-sex hormone treatment, but more information is needed. 
Lipids were measured in a study that followed transgender individuals for one 
year, while they received cross-sex hormones. The results for MtF transgender 
subjects, who were administered estrogen and anti-androgen, were increases in 
high-density lipoprotein (HDL) and triglycerides (TG) and decreases in low-
density lipoprotein (LDL). No changes were seen in total cholesterol, very low-
density lipoprotein (VLDL) and free fatty acids (FFA). FtM transgender subjects 
who were administered testosterone had decreased HDL and increased TG. No 
changes were observed in total cholesterol, LDL, VLDL and FFA (Elbers et al., 
2003). Similar results were found in studies done by Berra et al. 2006 and Giltay 
et al. 1999. The effects of estrogen and anti-androgen on HDL and TG in genetic 
females were further supported by a systematic review and meta-analysis of the 
available literature (Elamin et. al 2010). Complications arise from different routes 
of administration of hormones, which can in result in varying lipid levels 
(Coleman et al., 2011). Also both endogenous and exogenous testosterone is 
aromatized to estrogens in the periphery, which makes it difficult to fully 
understand its affect on the lipid profile. 
Evidence for the effects of cross-sex hormones on blood pressure is 
varying. Nonetheless hypertension is a stated risk for transgender individuals 
pursuing hormone therapy. Determining how great of a risk it poses remains up 
for debate. In a large scale study of mortality and morbidity in transgender 
individuals, hypertension (>160/95 mmHg) was only seen in 12 of 293 FtM and 
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61 of 816 MtF patients, which is on par with the prevalence in the general 
population (P. J. M. Van Kesteren et al., 1997). A study of 37 transgender 
individuals found that after a year of estrogen and anti-androgen treatment MtF 
subjects displayed significant increases in systolic and diastolic blood pressures, 
while administration of testosterone for one year in FtM subjects led to no change 
in systolic or diastolic blood pressures (Elbers et al., 2003). Furthermore, in a 
group of 74 FtM transgender individuals taking testosterone, over a three to four 
month period, had decreasing systolic and diastolic blood pressures (Giltay, 
Gooren, 2004). Blood pressure is also influenced by arterial stiffness. The effects 
of sex hormones on it have been explored with mixed results. In order to 
determine arterial stiffness, researchers calculated the compliance coefficient, 
which is an expression for the buffering capacity of the blood vessel wall, and the 
distension coefficient, which is an expression for the elasticity of the blood vessel 
wall. These coefficients were calculated for the common carotid, the femoral, and 
the brachial arteries in thirty transgender individuals who were administered 
cross-sex hormones over a period of one year. Following treatment, the result 
was an increase in femoral and brachial artery stiffness in MtF transgender 
subjects and no change in arterial stiffness in FtM transgender subjects. Blood 
pressure was also measured during the course of the study with MtF transgender 
subjects remaining constant, and FtM transgender subjects having a slight 
increase in systolic blood pressure (Giltay et al., 1999). Conversely, using flow-
mediated dilation (FMD), a study of twelve FtM transgender individuals taking 
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high-dose androgens were found to have increased brachial artery diameter, 
reduced response to nitroglycerin and a slight decrease in FMD when compared 
with age-matched controls. This lead the investigators to the conclusion that 
long-term use of high dose androgens results in increased arterial stiffness 
(McCredie et al., 1998). A similar result of decreased vascular reactivity i.e. 
increased arterial stiffness was observed in hypogonadal men treated with 
testosterone (Zitzmann, 2002). The findings of Giltay et al. 1999 are again 
contrasted, in regards to the effect of high-dose estrogen use in genetic males. 
Several studies found that vascular reactivity in fact increased in MtF 
transgender individuals when administered estrogen (McCrohon et al., 1997; 
New et al., 1997; New, Duffy, Harper, & Meredith, 2000). The ultimate effect of 
cross-sex hormones on blood pressure still requires further understanding, and 
hopefully with the elucidation of the mechanism in which sex hormones act upon 
the vasculature we will gain that understanding. What can be said from the 
reviewed studies is that even though they produced contrasting results, the 
effects on blood pressure and arterial stiffness were minimal.   
Another point of contention among researchers has been what is the 
effect of sex hormones on insulin resistance. The evidence varies. In one study, 
insulin resistance was induced and measured using a hyperinsulemic euglycemic 
clamp in MtF and FtM transgender individuals receiving estradiol and 
testosterone treatment respectively (Polderman et al., 1994). Another 
demonstrated that when administered estrogen and anti-androgen MtF 
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transgender subjects experienced insulin resistance, however testosterone 
administration in FtM subjects did not lead to insulin resistance unless a 
supraphysiological level of testosterone was given (Elbers et al., 2003). When 
given long-acting testosterone undecanoate in a one year open label study, FtM 
patients showed little difference in insulin resistance over the course of the study 
(Meriggiola et al., 2008). Finally, in a study comparing transgender individuals on 
hormone therapy to gender matched controls over a period of about 7 years an 
increased incidence of type 2 diabetes was observed (Wierckx et al., 2013).  
  The understanding of hormone replacement therapy in other disorders 
like male hypogonadism, ovarectomized women and post-menopausal women 
can provide investigators with insight into the risk factors involved in the 
treatment of transgender individuals and vice versa.  In an effort to better 
understand the relationship between sex hormones and Metabolic Syndrome, we 
can look to Polycystic Ovarian Syndrome (PCOS) for clues. There appears to be 
mutiple overlaps between FtM transgender individuals on hormone therapy and a 
patient with PCOS according to the current criteria. Various bodies have 
attempted to classify PCOS, however the definition is evolving. First, the 1990 
NIH conference chose diagnostic criteria for PCOS and ordered them by 
importance. They deemed hyperandrogenism and/or hyperandrogenemia most 
important followed by oligo-ovulation, and exclusion of other disorders (Azziz et 
al., 2011). In 2003, the Rotterdam Consensus revised the PCOS criteria. They 
determined that only two of the three criteria were necessary for diagnosis. 
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Those being oligo- and/or anovulation, clinical and/or biochemical signs of 
hyperandrogenism, polycystic ovaries and exclusion of other etiologies 
(congenital adrenal hyperplasias, androgen-secreting tumors, Cushing's 
syndrome) (The Rotterdam ESHRE/ASRM-sponsored PCOS consensus 
workshop group, 2004). Most recently, the Androgen Excess Society classified 
PCOS as a disorder primarily of androgen excess (Azziz et al., 2006). The effect 
of the changing criteria has been an expansion of the population of women 
considered to have PCOS. Presently, it is believed that greater than 10% of 
women worldwide could be affected by PCOS (Azziz et al., 2011). The changing 
criteria also demonstrates our lack of understanding of the etiology of the 
disorder. Its basis could founded in insulin resistance, adipose tissue dysfunction, 
abnormal steroidogenesis or hypothalamic-pituitary-ovarian dysregulation. The 
challenge lies in the fact that not all of these are present in any given patient 
(Azziz et al., 2011).  
 Many investigators believe a link exists between PCOS and FtM 
transgender individuals. That link may be hyperandrogenism. Those who are 
diagnosed with PCOS often present with symptoms of Metabolic Syndrome, 
which increases their of risk of developing diabetes and cardiovascular disease 
(Guzick, 2004). FtM transgender individuals are also made aware of their risk of 
developing Metabolic Syndrome, diabetes, and cardiovascular disease when 
administered high-dose androgens. Another similarity researchers have 
observed is the induction of polycystic ovaries following long-term high-dose 
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androgen exposure in FtM transgender individuals (Gooren & Giltay, 2008). 
Other investigators have recognized the similarities in diagnostic criteria between 
PCOS and FtM transgender individuals. Using the Rotterdam criteria, a study of 
Japanese FtM transgender individuals found them to have an increased 
incidence of PCOS and hyperandrogenaemia (Baba et al., 2007). Vujovic et al. 
2009 determined PCOS to be two times more prevalent in FtM transgender 
individuals than in the general population. It is interesting to examine this overlap, 
but the real importance lies in determining the clinical risk and relevance.  
So, what are the underlying interactions between androgens and insulin? 
This question has led to some interesting research and theories. It can be argued 
that if androgens induce insulin resistance and insulin promotes ovarian theca 
cell growth and androgen synthesis (Baptiste, 2010; Duleba, Spaczynski, & 
Olive, 1998) then the two are involved in a self-sustaining cycle. Serum hormone 
binding globulin (SHBG) may also be contributing to the interplay between 
androgens and insulin. Decreased levels of SHBG, as observed in some PCOS 
patients, could lead to increases in serum testosterone. Following a study where 
diazoxide, a drug which decreases insulin secretion, led to increases in SHBG 
levels Baptiste 2010 postulated that insulin may inhibit SHBG secretion from the 
liver. An alternative approach has focused on the function of adiponectin, an 
adipocyte specific protein. It is hypothesized that adiponectin levels are 
influenced by androgens and insulin resistance (Ardawi & Rouzi, 2005). 
Nishizawa et al. 2002 claims that androgens act directly on adipocytes 
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decreasing serum adiponectin, and because adiponectin is an insulin-sensitizing 
hormone this leads to insulin resistance. A more recent study asserts that 
decreases in adiponectin receptors on theca cells and adiponectin serum levels 
are involved in hyperandrogenism in PCOS patients (Comim, Hardy, & Franks, 
2013). Much of this information requires further exploration, but it provides an 
idea of the complex mechanisms that regulate the interactions between 
androgens and insulin.  
 
OBJECTIVES 
 The transgender community requires more evidence of the risk factors 
involved in hormone therapy, and how it will affect their quality of life. The only 
way this can be achieved is to share and contribute clinical data. Therefore, the 
goal of this project is to look at data collected as part of quality control monitoring 
of the Endocrinology Clinic at Boston Medical Center, where transgender 
patients are treated. Data gathered from a small portion of the individuals who 
frequent the clinic will be used to improve care and further understand the effects 
of cross-sex hormones on prolactin levels, potassium levels, lipids and insulin 
resistance in transgender individuals. With that information the aim will be to 
determine if there is any correlation between high-dose testosterone or estrogen 
treatment and the above values.  
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METHODS  
Overview: 
A group of 28 randomly selected transgender patients, who sought care 
from Dr. Joshua Safer through the Endocrinology Clinic at BMC, were selected to 
be retrospectively reviewed for a quality control study. The data on these 
individuals was collected by a HIPPA certified BU/BMC employee, and 
subsequently de-identified i.e. removed of all patient identifiers including name, 
date of birth and medical record number. Each patient was then assigned a study 
number. The data recorded includes: total testosterone, estradiol, high-density 
lipoprotein, low-density lipoprotein, triglycerides, hemoglobin A1c, prolactin, 
potassium, vitamin D, individual patient hormone therapy regimens, co-
morbidities, gender transition status, year of birth, and month and year of 
appointments. These values are stored in an Excel file and organized by study 
number.  
Analyses: 
Subjects were analyzed both individually and as groups based on gender.  
Individual analysis involved selecting study participants with the most complete 
data profiles i.e. fewest number of missing data points. Four of the six FtM and 
11 of the 22 MtF subjects were chosen. Change in total testosterone, estradiol, 
high-density lipoprotein, low-density lipoprotein, triglycerides and Vitamin D from 
baseline to 24 ± 3 months were plotted for the FtM subjects. Change in total 
testosterone, estradiol, high-density lipoprotein, low-density lipoprotein, 
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triglycerides, prolactin, potassium and Vitamin D were plotted for the MtF 
subjects. 
Group analysis was focused on determining if there was any correlation 
between changing T and E2 in MtF and FtM subjects and the other lab values 
recorded. The first round of calculations involved Pearson Correlation coefficients 
for both T and E2 versus HbA1c.  The criteria for analyses were first subjects 
needed two or more HbA1c measurements over the time that they sought 
treatment, and second there needed to be more than two individuals with multiple 
measurements. Therefore, because only two FtM transgender subjects had two 
or more HbA1c measurements, only the MtF transgender participants were 
analyzed. Participant’s data were placed in tables that organized it by study id 
number and lab values divided into 12-month intervals after baseline. Baseline 
was defined as the first set of lab values, however T and E2 values that were 
clearly representative of previous hormone therapy were excluded. T, E2 and 
HbA1c values within each time interval were averaged and the standard 
deviation was calculated. The averaged values were plotted and the Pearson 
Correlation coefficient was calculated along with a t-test to determine the 
statistical significance.  
The second set of calculations involved the same procedure and analysis 
criteria for comparing T and E2 with HbA1c, but were carried out while analyzing 
how T and E2 varied with changing TG, HDL, LDL levels in both MtF and FtM 
transgender participants. This procedure was also used to analyze T versus K 
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and E2 versus prolactin in MtF transgender subjects. Vitamin D levels were also 
followed, but were compared with the length of time that the individual received 
treatment. The only difference in analysis between HbA1c and the other lab data 
was the HbA1c values were divided into 12-month intervals as opposed to 5-
month intervals for everything else. Pearson Correlation coefficients were 
calculated for all of these along with t-tests for statistical significance. 
RESULTS 
Table 2: Number of Participants and Ages 
 MF FM 
# of individuals  22 6 
Age Groups 
18-29 5 2 
30-39 7 0 
40-49 3 1 
50-59 3 1 
60-69 4 1 
70-79 0 1 
 
Table 3: Co-morbidities 
 MF FM 
# of individuals  22 6 
Diabetes 5 1 
Hypertension 3 0 
Hyperlipidemia 4 2 
Psychiatric Diagnoses  3 2 
 
Table 4: Hormone Therapy 
 MF FM 
Oral Conjugated Esters (Premarin) 3 N/A 
Oral Esterified Estradiol 14 N/A 
Transdermal Estradiol 1 N/A 
Spironolactone (ALD) 16 N/A 
Testosterone Esters N/A 6 
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Individual Analysis of FtM Transgender Patients 
 
Table 5: Change in Hormone, Lipid and Vitamin D Levels From Baseline to 24±3 
Months in Treatment 
FM 
Subject 
# 
ΔT ΔE2 ΔHDL ΔLDL ΔTG ΔVitamin D 
3 +795 +3  -7 -31 +7 -4.3 
8 +646 -140.5 -13 +19 +86.5 -4 
11 +634 Missing Data -15 +82 -271 -8 
14 +1444 Missing Data +3 -102 -30 +33 
 
Figure 1 
Change in Testosterone from Baseline to 24 Months in FtM Transgender Individuals
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Figure 2 
Change in Estrogen from Baseline to 24 Months in FtM Transgender Individuals
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Figure 3 
Change in HDL from Baseline to 24 Months in FtM Transgender Individuals
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Figure 4 
Change in LDL from Baseline to 24 Months in FtM Transgender Individuals
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Figure 5 
Change in TG from Baseline to 24 Months in FtM Transgender Individuals
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Figure 6 
Change in Vitamin D from Baseline to 24 Months in FtM Transgender Individuals
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Individual Analysis of MtF Transgender Patients 
 
Table 6: Change in Hormone, Lipid, Potassium, Prolactin and Vitamin D Levels 
From Baseline to 24±3 Months in Treatment 
MF 
Subject # 
ΔT ΔE2 ΔHDL ΔLDL ΔTG ΔK ΔProlactin ΔVit D 
7 -330 +7 +3 -5 +330 +0.1 +4.8 +14 
12 +135 Missing Data +2 +4 -148 +0.3 +0.4 +4 
13 -148 +92 +2 +34 -15 +0.7 +3.7 -1 
15 -203 -32 -18 +3 +33 No change -2 -4 
17 -338 +20 +20 -8 +4 +1.1 Missing Data +21 
20 -259 Missing Data +27 +5 -30 -0.1 +29 -4 
21 -361 -10 +6 -23 +69 -0.8 +11.4 +5 
22 -363 +29 -10 +2 -23 No Change +11 +27 
24 -127 +88 +7 -19 +60 -0.1 +3 -2 
28 -59 +281 +19 -8 -89 -1.2 -3.9 +14 
29 +88 +48 +1 +43 +195 -1 +4.7 Missing Data 
 
Figure 7 
Change in Testosterone from Baseline to 24 Months in MtF Transgender Individuals
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Figure 8 
Change in Estrogen from Baseline to 24 Months in MtF Transgender Individuals
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Figure 9 
Change in HDL from Baseline to 24 Months in MtF Transgender Individuals
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Figure 10 
Change in LDL from Baseline to 24 Months in MtF Transgender Individuals
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Figure 11 
Change in Triglycerides from Baseline to 24 Months in MtF Transgender Individuals
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Figure 12 
Change in Potassium from Baseline to 24 Months in MtF Transgender Individuals
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Figure 13 
Change in Prolactin from Baseline to 24 Months in MtF Transgender Individuals
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Figure 14 
Change in Vitamin D from Baseline to 24 Months in MtF Transgender Individuals
0
5
10
15
20
25
30
35
40
45
50
0 5 10 15 20 25 30
Time (months)
V
it
a
m
in
 D
 (
n
g
/
m
L
)
7
12
13
15
17
20
21
22
24
28
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
Group Analysis of Transgender Patients 
 
Figure 15 
How HbA1c Varies with Testosterone and Estrogen Levels in MtF Transgender Individuals
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Table 7: Average Testosterone, Estrogen and HbA1c Values Over Time in MtF 
Transgender Individuals 
Months 0 1-12 13-24 25-36 
Average T±SD (ng/dL) 341.7±196.3 189.5±122.3 164.6±159.1 97.0±70.7 
n (T) 4 4 5 2 
Average E2±SD (pg/dL) 51.0±21.3 202.3±161.3 90.2±66.7 52.0±32.5 
n (E2) 4 3 5 2 
Average HbA1c±SD (%) 6.7±1.0 6.9±0.9 6.5±1.5 5.6±0.9 
n (HbA1c) 5 6 6 2 
r (T, HbA1c) = 0.645099178, t = 1.19, df = 2, p > 0.05 
r (E2, HbA1c) = 0.594488776, t = 1.05, df = 2, p > 0.05 
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Figure 16 
How Triglyceride Levels Vary with Testosterone Levels in MtF and FtM Transgender Individuals
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Table 8: Average Testosterone and Triglycerides Over Time in MtF Transgender 
Individuals 
Months Average T±SD (ng/dL) n(T) Average TG±SD (mg/dL) n(TG) 
0 425.4±359.1 17 135.3±73.2 14 
1-5 436.7±393.2 11 134.2±90.8 10 
6-10 315.3±234.4 18 164.6±119.6 21 
11-15 298.5±234.1 15 169.9±104.9 14 
16-20 283.6±295.4 15 204.8±143.3 13 
21-25 147.1±144.7 11 199.6±175.2 13 
26-30 273.4±358.6 9 188.7±106.0 7 
31-35 140.6±112.8 8 184.3±96.0 8 
r(MtF) = -0.82, t = 3.54 df = 6, p<0.05 
Table 9: Average Testosterone and Triglycerides Over Time in FtM Transgender 
Individuals 
Months Average T±SD (ng/dL) n(T) Average TG±SD (mg/dL) n(TG) 
0 44.5±32.4 4 114.6±60.2 4 
1-5 495.4±302.3 5 153.7±35.9 3 
6-10 787.6±193.3 5 163.6±122.0 5 
11-15 943.3±301.2 5 169.3±120.9 6 
16-20 561.0±121.6 2 155.7±85.5 3 
21-25 820.0±365.9 6 263.0±112.9 5 
r(FtM) = 0.65, t = 1.72, df = 4, p>0.05 
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Figure 17: 
How Triglyceride Levels Vary with Estrogen Levels in MtF and FtM Transgender Individuals 
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Table 10: Average Estrogen and Triglycerides Over Time in MtF Transgender 
Individuals 
Months Average E2±SD (pg/dL) n(T) Average TG±SD (mg/dL) n(TG) 
0 42.0±17.5  15 135.3±73.2 14 
1-5 95.8±92.4 11 134.2±90.8 10 
6-10 70.8±57.7 19 164.6±119.6 21 
11-15 61.1±39.5 13 169.9±104.9 14 
16-20 87.5±119.3 11 204.8±143.3 13 
21-25 102.5±78.7 13 199.6±175.2 13 
26-30 163.3±261.8 8 188.7±106.0 7 
31-35 119.9±115.7 7 184.3±96.0 8 
r(MtF) = 0.50, t = 1.43 df = 6, p>0.05 
Table 11: Average Estrogen and Triglycerides Over Time in FtM Transgender 
Individuals 
Months Average E2±SD (pg/dL) n(T) Average TG±SD (mg/dL) n(TG) 
0 65.1±60.4 5 114.6±60.2 4 
1-5 145.5±156.3 2 153.7±35.9 3 
6-10 85.0±45.25 2 163.6±122.0 5 
11-15 76.0±22.63 2 169.3±120.9 6 
16-20 52.0±39.6 2 155.7±85.5 3 
21-25 43.0±7.8 3 263.0±112.9 5 
r(FtM) = -0.48, t = 1.09, df = 4, p>0.2 
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Figure 18: 
How HDL Levels Vary with Testosterone Levels in MtF and FtM Transgender Individuals
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Table 12: Average Testosterone and HDL Over Time in MtF Transgender 
Individuals 
Months Average T±SD (ng/dL) n(T) Average HDL±SD (mg/dL) n(HDL) 
0 425.4±359.1 17 52.9±17.3 14 
1-5 436.7±393.2 11 47.8±10.9 10 
6-10 315.3±234.4 18 52.9±16.8 21 
11-15 298.5±234.1 15 54.1±20.9 14 
16-20 283.6±295.4 15 52.6±17.3 13 
21-25 147.1±144.7 11 51.7±10.6 13 
26-30 273.4±358.6 9 56.5±16.8 6 
31-35 140.6±112.8 8 50.6±5.9 7 
r(MtF) = -0.15, t = 0.3 df = 6, p>0.2 
Table 13: Average Testosterone and HDL Over Time in FtM Transgender 
Individuals 
Months Average T±SD (ng/dL) n(T) Average HDL±SD (mg/dL) n(HDL) 
0 44.5±32.4 4 45.0±4.5 4 
1-5 495.4±302.3 5 44.3±14.3 3 
6-10 787.6±193.3 5 70.2±71.0 5 
11-15 943.3±301.2 5 40.7±8.2 6 
16-20 561.0±121.6 2 37.0±4.2 2 
21-25 820.0±365.9 6 39.2±13.4 5 
r(FtM) = 0.12, t = 0.23, df = 4, p>0.2 
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Figure 19: 
How HDL Levels Vary with Estrogen Levels in MtF and FtM Transgender Individuals
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Table 14: Average Estrogen and HDL Over Time in MtF Transgender Individuals 
Months Average E2±SD (pg/dL) n(T) Average HDL±SD (mg/dL) n(HDL) 
0 42.0±17.5 15 52.9±17.3 14 
1-5 95.8±92.4 11 47.8±10.9 10 
6-10 70.8±57.7 19 52.9±16.8 21 
11-15 61.1±39.5 13 54.1±20.9 14 
16-20 87.5±119.3 11 52.6±17.3 13 
21-25 102.5±78.7 13 51.7±10.6 13 
26-30 163.3±261.8 8 56.5±16.8 6 
31-35 119.9±115.7 7 50.6±5.9 7 
r(MtF) = 0.19, t = 0.49 df = 6, p>0.2 
Table 15: Average Estrogen and HDL Over Time in FtM Transgender Individuals 
Months Average E2±SD (pg/dL) n(T) Average HDL±SD (mg/dL) n(HDL) 
0 65.1±60.4 5 45.0±4.5 4 
1-5 145.5±156.3 2 44.3±14.3 3 
6-10 85.0±45.25 2 70.2±71.0 5 
11-15 76.0±22.63 2 40.7±8.2 6 
16-20 52.0±39.6 2 37.0±4.2 2 
21-25 43.0±7.8 3 39.2±13.4 5 
r(MtF) = 0.25, t = 0.51, df = 4, p>0.2 
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Figure 20: 
How LDL Levels Vary with Testosterone Levels in MtF and FtM Transgender Individuals
0
20
40
60
80
100
120
140
160
0 100 200 300 400 500 600 700 800 900 1000
Average Testosterone (ng/dL)
A
v
e
ra
g
e
 L
D
L
 (
m
g
/
d
L
)
MtF
FtM
 
Table 16: Average Testosterone and LDL Over Time in MtF Transgender 
Individuals 
Months Average T±SD (ng/dL) n(T) Average LDL±SD (mg/dL) n(LDL) 
0 425.4±359.1 17 97.0±31.8 15 
1-5 436.7±393.2 11 91.1±28.8 10 
6-10 315.3±234.4 18 94.5±31.8 20 
11-15 298.5±234.1 15 100.8±36.0 13 
16-20 283.6±295.4 15 115.4±34.5 14 
21-25 147.1±144.7 11 84.4±21.9 11 
26-30 273.4±358.6 9 92.0±20.9 5 
31-35 140.6±112.8 8 78.1±27.6 7 
r(MtF) = 0.43, t = 1.18 df = 6, p>0.2 
Table 17: Average Testosterone and LDL Over Time in FtM Transgender 
Individuals 
Months Average T±SD (ng/dL) n(T) Average LDL±SD (mg/dL) n(LDL) 
0 44.5±32.4 4 151.7±40.1 4 
1-5 495.4±302.3 5 126.0±80.6 3 
6-10 787.6±193.3 5 95.2±39.2 5 
11-15 943.3±301.2 5 111.0±38.4 6 
16-20 561.0±121.6 2 117.0±68.1 3 
21-25 820.0±365.9 6 116.4±34.9 5 
r(FtM) = -0.88, t = 3.68, df = 4, p<0.05 
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Figure 21: 
How LDL Levels Vary with Estrogen Levels in MtF and FtM Transgender Individuals
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Table 18: Average Estrogen and LDL Over Time in MtF Transgender Individuals 
Months Average E2±SD (pg/dL) n(T) Average LDL±SD (mg/dL) n(LDL) 
0 42.0±17.5 15 97.0±31.8 15 
1-5 95.8±92.4 11 91.1±28.8 10 
6-10 70.8±57.7 19 94.5±31.8 20 
11-15 61.1±39.5 13 100.8±36.0 13 
16-20 87.5±119.3 11 115.4±34.5 14 
21-25 102.5±78.7 13 84.4±21.9 11 
26-30 163.3±261.8 8 92.0±20.9 5 
31-35 119.9±115.7 7 78.1±27.6 7 
r(MtF) = -0.39, t = 1.07 df = 6, p>0.2 
Table 19: Average Estrogen and LDL Over Time in FtM Transgender Individuals 
Months Average E2±SD (pg/dL) n(T) Average LDL±SD (mg/dL) n(LDL) 
0 65.1±60.4 5 151.7±40.1 4 
1-5 145.5±156.3 2 126.0±80.6 3 
6-10 85.0±45.25 2 95.2±39.2 5 
11-15 76.0±22.63 2 111.0±38.4 6 
16-20 52.0±39.6 2 117.0±68.1 3 
21-25 43.0±7.8 3 116.4±34.9 5 
r(FtM) = 0.03, t = 0.13, df = 4, p>0.2 
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Figure 22: 
Vitamin D Levels Over Time in MtF and FtM Transgender Individuals
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Table 20: Average Vitamin D Level Over Time in MtF and FtM Transgender 
Individuals 
Months MtF Average Vit D±SD 
(ng/mL) 
N(MtF) FtM Average Vit D±SD 
(ng/mL) 
n(FtM) 
0 21.5±9.9 16 25.1±8.5  3 
1-5 25.1±13.5 8 29.7±4.6 3 
6-10 24.6±12.3 19 32.5±12.7 4 
11-15 27.6±9.1 13 29.3±15.4 4 
16-20 27.5±15.2 12 25.0±14.1 2 
21-25 31.0±7.9 10 29.0±14.3 5 
26-30 33.2±7.0 6 N/A N/A 
31-35 30.7±10.6 7 N/A N/A 
r (MtF) = 0.93, t = 6.41, df = 6, p < 0.01 
r (FtM) = 0.04, t = 0.09, df = 4, p > 0.2 
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Figure 23: 
How Prolactin Levels Vary with Estrogen Levels in MtF Transgender Individuals
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Table 21: Average Estrogen and Prolactin Levels in MtF Transgender Individuals 
Months Average E2±SD 
(pg/dL) 
n(T) Average Prolactin±SD 
(ng/mL) 
n(Prolactin) 
0 42.0±17.5 15 8.1±3.9 17 
1-5 95.8±92.4 11 7.9±3.3 11 
6-10 70.8±57.7 19 9.6±4.6 19 
11-15 61.1±39.5 13 9.5±5.7 14 
16-20 87.5±119.3 11 11.9±9.1 13 
21-25 102.5±78.7 13 9.4±4.4 12 
26-30 163.3±261.8 8 17.5±13.1 8 
31-35 119.9±115.7 7 8.2±4.9 5 
r(prolactin) = 0.69, t = 2.33, df = 6, p < 0.1 
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Figure 24: 
How Potassium Levels Vary with Testosterone Levels in MtF Transgender Individuals
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Table 22: Average Testosterone and Potassium Levels in MtF Transgender 
Individuals 
Months Average T±SD (ng/dL) n(T) Average K±SD (nmol/L) n(K) 
0 425.4±359.1 17 4.3±0.3 16 
1-5 436.7±393.2 11 4.3±0.6 11 
6-10 315.3±234.4 18 4.4±0.3 18 
11-15 298.5±234.1 15 4.5±0.3 14 
16-20 283.6±295.4 15 4.4±0.4 13 
21-25 147.1±144.7 11 4.7±0.4 10 
26-30 273.4±358.6 9 4.1±0.5 6 
31-35 140.6±112.8 8 4.2±0.4 6 
r(K) = -0.29, t = 0.69, df = 6, p > 0.2 
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DISCUSSION 
Table 23: Recommended Lab Values (Gomella LG, Haist SA. eds., 2007) 
 Male Female 
Total Testosterone 300 – 1100 ng/dL <100 mg/dL  
Estrogen 10-60 pg/mL <50 pg/mL 
HDL (fasting) >40 mg/dL >40 mg/dL 
LDL (fasting) <160 mg/dL <160 mg/dL 
Triglycerides (fasting) <150 mg/dL <150 mg/dL 
HbA1c <6% <6% 
Prolactin 1-20 ng/mL 1-25 ng/mL 
Potassium 3.5-5 mEq/L 3.5-5 mEq/L 
Vitamin D >30 ng/mL >30 ng/mL 
 
 Performing a retrospective quality control analysis of transgender 
individuals seeking care proved to be both a unique and fascinating learning 
experience. The goal was to assess known risk factors in a clinical setting, which 
was accomplished by investigating changing lab values individually and as 
groups based on gender. This study gave a glimpse into an underserved and 
sometimes ostracized population whose therapy is under-documented and not 
fully understood. The project then looked at how HbA1c, an indicator of insulin 
resistance, is affected by hormone therapy. Even though this is on a small scale 
the investigation of HbA1c in transgender individuals has never been preformed 
before. We also observed Vitamin D levels over time as an indicator of the 
benefit of consistent clinical care. 
To start we looked at individual FtM patients. Due to lack of or missing 
data, four were chosen.  These subjects all took varying levels of weekly 
Testosterone Esters. At baseline, all four fell within the recommended total 
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testosterone value for females. Following two years of treatment, not surprisingly 
all were in the male range except one who exceeded it. This could be due to the 
measurement being taken following an injection i.e. a peak or possibly an 
inaccurate test. Individual assessment of estrogen change could not be done 
because only two individuals had usable measurements. Therefore, no 
conclusions could be drawn.  
Next, change in lipids were calculated and plotted. All of the lipid 
measurements done were non-fasting. One item to note is that patient 11 had 
hyperlidemia, which could be affecting their outcome. That being said, the four 
FtM subjects at baseline had normal fasting levels of HDL. The two-year 
measurement showed that three of the individuals had decreased HDL, which fell 
below the suggested fasting HDL levels (>40 mg/dL). The other person had a 
slight increase in HDL staying in the normal range. These results support 
previous studies (Elbers et al., 2003) where transgender men experienced 
decreased HDL with testosterone treatment.  
The baseline measurement of LDL had three of the subjects in the 
recommended value, while the fourth was above that. After two years of 
treatment, two individuals had increased and two had decreased LDL levels and 
all four ended up below 160 mg/dL. Even though Patient 11 stayed below 160 
mg/dL the difference in the measurements saw a dramatic increase (+82 mg/dL) 
over the two-year period, which could be the reasoning behind the hyperlipidemia 
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diagnosis. Evidence of the effects of testosterone on LDL levels are mixed, 
however Berra et al., 2006 found no change in LDL levels.  
Measurement of triglycerides in the four transgender men, at baseline, 
showed that two individuals were in the suggested fasting range and two were 
above it. The triglyceride measurements taken after two years showed an 
increase for two and a decrease for two individuals. Patient 11 again showed the 
most dramatic change, having a decrease of 271 mg/dL. The mixed results 
shown here contrast those that have been published, which show increases in 
TG level following T administration.   
Observation of Vitamin D levels showed two individuals above and two 
below the recommended level (30 mg/dL) at baseline. After two years, three 
individuals had slight decreases, but two remained above 30 mg/dL. The final 
patient managed a large increase putting them at greater than 50 mg/dL. 
Although this is not hard evidence, it does represent a side benefit of those in this 
population who maintain regular care.  
Due to the small sample size, it is difficult to draw any conclusions or 
notice any trends in the individual assessment of FtM patients receiving care at 
the clinic. However, even with the small sample size some results from the lipid 
panel do coincide with current research. If administration of masculinizing 
hormones, and not outside factors, are leading to these changes then it would 
add evidence to the risk, but because many variables still remain the debate 
continues.  
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 The second set of individual analysis dealt with a group of MtF 
transgender patients, who had their lab values compared and plotted over a two-
year period. Of the eleven patients chosen there were a variety of daily hormone 
regimens administered. These included oral esterified estrogen, transdermal 
estrogen and oral conjugated estrogen. Each form of estrogen was taken in 
combination with spironolactone, an anti-androgen. At baseline, four fell out of 
the recommended range of T including three below it. Of the 11 patients 
observed, 9 had decreases in total testosterone over 2 years. The average 
decrease in T in those nine was 243.1±113.5 ng/dL. Increases in E2 were 
observed in 8 of the 11 patients with an average increase of 80.7±113.5 pg/dL, 
however this includes patient 28 who had a large increase in estrogen. With most 
patients seeing an increase in E2 and a decrease in T, albeit to varying degrees, 
it agrees with the typical trend of transitioning transgender women.  
 Similar to the FtM patients, the majority of the MtF subjects stayed within 
the recommended levels of fasting HDL at baseline and at the two-year 
measurement, even though the measurements were non-fasting. Nine of the 
eleven participants had increases in HDL. This result contrasts that found in the 
Elbers et al., 2003 study where HDL levels decreased in transgender women. 
One difference is those patients were all administered oral estrogen and 
cyproterone acetate, an alternative anti-androgen. One explanation for this 
difference is as Coleman et al., 2011 stated the route of administration of 
estrogen can have an effect on lipid metabolism.  
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Despite the variety of baseline LDL levels all MtF patients fell below 160 
mg/dL, the suggested LDL level. Even at the two year measurement all of the 
patients still had LDL levels below 160 mg/dL except patient 13 who an increase 
putting them over 160 mg/dL. Patient 29 also experienced a large increase, 
however still remained in the recommended range. Besides those two patients 
there were a mixture of increases and decreases in LDL level making it difficult to 
determine any trend. Like LDL, individual assessment of TG levels yielded no 
discernible result due to the wide range of TG levels between patients and 
between the baseline and two year measurements. It should be noted that both 
patient 12 and 21 had hyperlipidemia. Their HDL and LDL levels did not have 
much of a change between the baseline and two-year measurements, however 
patient 12 had a large decrease and patient 21 had a large increase in TG over 
the same time period.  
 Spironolactone provides the benefit of acting as an anti-androgen in MtF 
transgender individuals. There is a risk that is could lead to hyperkalemia 
especially when mixed with angiotensin converting enzyme inhibitors (Juurlink et 
al., 2004). That risk seems to be unrealized in our individual evaluation. The 
majority of the patients observed stayed within the normal range between the two 
measurements and if change was experienced it was only minimal.       
The results for prolactin levels were more homogeneous. All patients 
remained in the recommended range at baseline and at two years, except for 
patient 20 who experienced a drastic increase. Of the 11 patients, eight 
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experienced increases in prolactin. The average increase was 8.5±8.5 ng/mL. 
This is consistent with the literature, which shows that transgender women 
experience increases in prolactin with estrogen administration. 
Change in Vitamin D over the observation period yielded interesting 
results. At baseline only three individuals were above the suggested level of 
Vitamin D. At the two-year measurement, nine were above or around 30 ng/mL. 
This further demonstrates a positive effect of consistent care for transgender 
individuals. This is a small piece of evidence for the benefit of clinical intervention 
in these individuals, who are often marginalized and at times avoid treatment due 
to social stigma. 
We then moved on to the group analysis, where correlation coefficients (r) 
were calculated, in an effort to better understand if changing hormone levels 
were associated with the recorded lab values over time. The first correlation 
performed was for HbA1c. It is a good indicator of diabetes because it represents 
blood sugar over a three-month period. Unfortunately, it has yet to be 
incorporated in current transgender research. Once it is it could help our 
understanding of how cross-sex hormones affect indicators of Metabolic 
Syndrome and its associated diseases. Calculation of the correlation coefficient 
yielded mid-level positive correlations for both T/HbA1c and E2/HbA1c in the MtF 
transgender group. Neither of the correlation coefficients were considered to be 
statistically significant. This could be due to the very low sample size. Another 
complicating factor was two of the five individuals in the group had diabetes, 
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which if uncontrolled can lead to HbA1c levels greater than 6%. Even with the 
unreliability of these statistics the results still could be used as supporting 
evidence for the continued monitoring of HbA1c levels in transgender individuals. 
 Yet another indicator of Metabolic Syndrome is dyslipidemia, and 
therefore the next focus of the discussion. First, TG levels were looked at in both 
genders. The results of the analysis were interesting, but nothing concrete could 
be resolved from them. A strong, statistically significant, negative correlation was 
found between T and TG levels in MtF individuals. This means as T decreased 
TG increased. One might assume that in turn a positive correlation would be 
found between E2 and TG in MtF individuals, but in fact only a positive, mid-
level, non-statistically significant correlation was determined. In the FtM group of 
patients, mid-level non-statistically significant correlations were calculated for 
both T/TG and E2/TG. Next, HDL was compared with both T and E2 over time. 
Little to no correlation was found between HDL and T/E2 in both genders. Finally, 
LDL was compared to both hormones. Of the four calculations of correlation 
coefficients only the relationship between T and LDL in FtM patients was deemed 
statistically significant. The result was a strong negative correlation meaning as T 
increased LDL decreased, which is not in agreement with the literature. 
Ultimately though, because there is no consensus in the literature as to the effect 
of hormone therapy on lipids the discussion continues.  
As mentioned previously Vitamin D levels could be evidence of the 
positive effect of consistent clinical care for transgender individuals. In the MtF 
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group a strong positive, statistically significant correlation was calculated. This 
means that as time went on Vitamin D levels increased. Unfortunately, in the FtM 
group no correlation was found between time and Vitamin D level, however 
based on the average Vitamin D level the FtM group experienced an increased 
average and stayed around the clinically recommended Vitamin D level 
throughout the observation period. These results could be considered further 
support of the hypothesis. 
Hyperprolactinemia is a known risk when administering exogenous 
estrogen (Coleman et al., 2011; Hembree et al., 2009). Our results showed a 
somewhat strong, yet not statistically significant, correlation between increasing 
E2 and prolactin in MtF transgender individuals. This correlation provides added 
evidence to link between exogenous estrogen and increased prolactin levels. 
 Since spironolactone has a side effect of hyperkalemia and because 
serum levels of spironolactone were unavailable we decided to compare 
changing T levels with potassium levels in the MtF patients. The reasoning here 
was because spironolactone acts as an anti-androgen there may be a correlation 
between decreasing T and increasing potassium. However, the calculation bore 
out no correlation between the two values probably due to little or no fluctuation 
in potassium levels over the observation period.  
Even with the value of the information collected from this project there 
were several limitations. First, the Pearson Correlation coefficient used in the 
group analysis is not a particularly robust test statistic. Outliers can affect its 
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value as well as small sample size, which unfortunately, this study falls victim to 
like many others who have studied transgender medicine. The second issue 
deals with hormone therapy and the nature of the data collected. Since all of the 
lab data came from patients currently seeking care nothing was standardized. 
This means that at times medication was self-administered and self-reported, 
leaving the possibility for over or under dosing. Self-reporting also can lead to 
inaccurately identifying peaks and troughs in hormone level. Many transgender 
individuals often in an effort to achieve their desired gender identity will turn to 
non-prescription hormones, which could complicate the data that was collected. 
Administration of cross-sex hormones by a clinician is not identical in every 
patient, therefore while trying to achieve the optimal hormone combination for the 
patient the data in some will reflect the change in prescription.  Since nothing 
was standardized no individual was excluded from analysis. This means that 
there were no controls; people from various age ranges and having different co-
morbidities etc. were included. All of these factors may affect outcome. The next 
issue was the definition of baseline. It was defined, as when the patient first 
began to seek treatment from the physician, not necessarily when hormone 
therapy began. Efforts were taken, though, to remove values that clearly 
represented that the individual was self-administering hormones previous to their 
initial clinic visit. Next, lab values were not consistent throughout the observation 
period, which could have resulted from a patient missing visits or the clinician not 
ordering the same tests. Also the lipid panels were non-fasting. This definitely 
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adds some variability into the results because for example diet must now be 
accounted for. The last point is how free testosterone is measured. The current 
methods are crude (Rosner et al., 2007), which make it difficult to get accurate 
results.  
This project should be used as a platform for future study. In terms of 
improving upon what has been done here, a multivariate analysis would serve to 
strengthen the results. It would allow for a better understanding of the individual 
effects of testosterone or estrogen on the observed values. Without this 
advanced analysis it remains difficult to decipher the interplay between these 
hormones. Further complicating this is the fact that testosterone is often 
aromatized to estrogens in the periphery, and thus more understanding of how 
this affects risk factors in transgender individuals would also be grounds for 
future study. This project would also benefit from a more complete analysis of 
HbA1c in transgender individuals, which may help to clear up the effect of cross-
sex hormones on insulin resistance. Finally, in order to better understand if there 
is a link between PCOS and transgender men a histological study of biopsied 
ovaries from FtM transgender individuals before and during testosterone 
treatment could bear new and useful information.  
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Conclusion 
What this project has accomplished, as was its hope, was to provide supporting 
evidence to previous studies that show that even though there is inherent risk in 
the use of exogenous hormones they are safe and the increased mortality rate in 
the transgender population is due to causes that are non-related to hormones 
(Asscheman et al., 2011). Furthering research in transgender medicine is 
important because of the general lack of understanding. The studies of this 
nature that are available are limited in number and often contain very small 
patient populations. Recording this data will help to clarify the risks and safety of 
long-term hormone administration in transgender individuals, which will also 
hopefully have the effect of expanding the understanding of transgender health. 
Often the question among clinicians when determining whether or not to treat a 
transgender patient is: are the risks worth the improvement in quality of life? 
Although this study cannot definitively prove that hormone therapy is safe, what it 
does show is glimpse into a clinical experience where real time changes were 
observed and recorded in transgender patients being safely administered 
hormones. Being able to recognize the risk factors and knowing they can be 
minimalized is important in transgender healthcare. It now behooves researchers 
to dive deeper and identify who is at risk for these changes and why. 
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